Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Share-based Compensation for 10 consecutive years, with $11.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 7.44% year-over-year to $11.6 million; the trailing twelve-month figure through Jun 2026 stood at $43.8 million (up 304.65% YoY), and the FY2025 full-year result was $90.4 million, up 138.39% from the prior year.
• Share-based Compensation rose to $11.6 million in Q2 2026 per KNSA's latest filing, from $10.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $11.9 million in Q3 2025 and bottomed at $6.4 million in Q4 2022.
• Historically, Share-based Compensation has averaged $10.2 million across 5 years, with a median of $10.6 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation fell 15.12% in 2022, then grew 23.34% in 2025.
• Over 5 years, Share-based Compensation stood at $6.4 million in 2022, then grew by 21.99% to $7.8 million in 2023, then advanced by 6.75% to $8.3 million in 2024, then grew by 23.34% to $10.2 million in 2025, then grew by 13.69% to $11.6 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $11.6 million, $10.1 million, and $10.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.